BACKGROUND & AIMS: Mutations in the DNA mismatch repair (MMR) gene MSH2 cause Lynch syndromes I and II and sporadic colorectal cancers. Msh2(null) mice predominantly develop lymphoma and do not accurately recapitulate the colorectal cancer phenotype. METHODS: We generated and examined mice with a conditional Msh2 disruption (Msh2(LoxP)), permitting tissue-specific gene inactivation. ECMsh2(LoxP/LoxP) mice carried an EIIa-Cre transgene, and VCMsh2(LoxP/LoxP) mice carried a Villin-Cre transgene. We combined the VCMsh2(LoxP) allele with either Msh2(Delta7null) (VCMsh2(LoxP/null)) or Msh2(G674D) mutations (VCMsh2(LoxP/G674D)) to create allelic phase mutants. These mice were given cisplatin or 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX), and their tumors were measured by magnetic resonance imaging. RESULTS: Embryonic fibroblasts from ECMsh2(LoxP/LoxP) mice do not express MSH2 and are MMR deficient. Reverse transcription, polymerase chain reaction, and immunohistochemistry from VCMsh2(LoxP/LoxP) mice demonstrated specific loss of Msh2 messenger RNA and protein from epithelial cells of the intestinal tract. Microsatellite instability was observed in all VCMsh2 strains and limited to the intestinal mucosa. Resulting adenomas and adenocarcinomas had somatic truncation mutations to the adenomatous polyposis coli (Apc) gene. VCMsh2(LoxP/LoxP) mice did not develop lymphoma. Comparison of allelic phase tumors revealed significant differences in multiplicity and size. When treated with cisplatin or FOLFOX, tumor size was reduced in VCMsh2(LoxP/G674D) but not VCMsh2(LoxP/null) tumors. The apoptotic response to FOLFOX was partially sustained in the intestinal mucosa of VCMsh2(LoxP/G674D) animals. CONCLUSIONS: Msh2(LoxP/LoxP) mice in combination with appropriate Cre recombinase transgenes have excellent potential for preclinical modeling of Lynch syndrome, MMR-deficient tumors of other tissue types, and use in drug development. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS: Mutations in the DNA mismatch repair (MMR) gene MSH2 cause Lynch syndromes I and II and sporadic colorectal cancers. Msh2(null) mice predominantly develop lymphoma and do not accurately recapitulate the colorectal cancer phenotype. METHODS: We generated and examined mice with a conditional Msh2 disruption (Msh2(LoxP)), permitting tissue-specific gene inactivation. ECMsh2(LoxP/LoxP) mice carried an EIIa-Cre transgene, and VCMsh2(LoxP/LoxP) mice carried a Villin-Cre transgene. We combined the VCMsh2(LoxP) allele with either Msh2(Delta7null) (VCMsh2(LoxP/null)) or Msh2(G674D) mutations (VCMsh2(LoxP/G674D)) to create allelic phase mutants. These mice were given cisplatin or 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX), and their tumors were measured by magnetic resonance imaging. RESULTS: Embryonic fibroblasts from ECMsh2(LoxP/LoxP) mice do not express MSH2 and are MMR deficient. Reverse transcription, polymerase chain reaction, and immunohistochemistry from VCMsh2(LoxP/LoxP) mice demonstrated specific loss of Msh2 messenger RNA and protein from epithelial cells of the intestinal tract. Microsatellite instability was observed in all VCMsh2 strains and limited to the intestinal mucosa. Resulting adenomas and adenocarcinomas had somatic truncation mutations to the adenomatous polyposis coli (Apc) gene. VCMsh2(LoxP/LoxP) mice did not develop lymphoma. Comparison of allelic phase tumors revealed significant differences in multiplicity and size. When treated with cisplatin or FOLFOX, tumor size was reduced in VCMsh2(LoxP/G674D) but not VCMsh2(LoxP/null) tumors. The apoptotic response to FOLFOX was partially sustained in the intestinal mucosa of VCMsh2(LoxP/G674D) animals. CONCLUSIONS:Msh2(LoxP/LoxP) mice in combination with appropriate Cre recombinase transgenes have excellent potential for preclinical modeling of Lynch syndrome, MMR-deficient tumors of other tissue types, and use in drug development. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: C I Rodríguez; F Buchholz; J Galloway; R Sequerra; J Kasper; R Ayala; A F Stewart; S M Dymecki Journal: Nat Genet Date: 2000-06 Impact factor: 38.330
Authors: E C Lee; D Yu; J Martinez de Velasco; L Tessarollo; D A Swing; D L Court; N A Jenkins; N G Copeland Journal: Genomics Date: 2001-04-01 Impact factor: 5.736
Authors: R Smits; N Hofland; W Edelmann; M Geugien; S Jagmohan-Changur; C Albuquerque; C Breukel; R Kucherlapati; M F Kielman; R Fodde Journal: Genes Chromosomes Cancer Date: 2000-11 Impact factor: 5.006
Authors: Kaichun Wei; Alan B Clark; Edmund Wong; Michael F Kane; Dan J Mazur; Tchaiko Parris; Nadine K Kolas; Robert Russell; Harry Hou; Burkhard Kneitz; Guohze Yang; Thomas A Kunkel; Richard D Kolodner; Paula E Cohen; Winfried Edelmann Journal: Genes Dev Date: 2003-03-01 Impact factor: 11.361
Authors: Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger Journal: N Engl J Med Date: 2003-07-17 Impact factor: 91.245
Authors: Ashley R Maiuri; Michael Peng; Ram Podicheti; Shruthi Sriramkumar; Caitlin M Kamplain; Douglas B Rusch; Christina E DeStefano Shields; Cynthia L Sears; Heather M O'Hagan Journal: Cancer Res Date: 2017-05-18 Impact factor: 12.701
Authors: Mary Kay Washington; Anne E Powell; Ruth Sullivan; John P Sundberg; Nicholas Wright; Robert J Coffey; William F Dove Journal: Gastroenterology Date: 2013-02-12 Impact factor: 22.682
Authors: Babar Bashir; Dante J Merlino; Jeffrey A Rappaport; Esteban Gnass; Juan P Palazzo; Ying Feng; Eric R Fearon; Adam E Snook; Scott A Waldman Journal: Hum Pathol Date: 2019-02-02 Impact factor: 3.466
Authors: K Keysselt; T Kreutzmann; K Rother; C Kerner; K Krohn; J Przybilla; P Buske; H Löffler-Wirth; M Loeffler; J Galle; G Aust Journal: Oncogene Date: 2016-12-12 Impact factor: 9.867
Authors: Daniel J McGrail; Jeannine Garnett; Jun Yin; Hui Dai; David J H Shih; Truong Nguyen Anh Lam; Yang Li; Chaoyang Sun; Yongsheng Li; Rosemarie Schmandt; Ji Yuan Wu; Limei Hu; Yulong Liang; Guang Peng; Eric Jonasch; David Menter; Melinda S Yates; Scott Kopetz; Karen H Lu; Russell Broaddus; Gordon B Mills; Nidhi Sahni; Shiaw-Yih Lin Journal: Cancer Cell Date: 2020-02-27 Impact factor: 31.743